Skip to main content
Premium Trial:

Request an Annual Quote

Quest Diagnostics

Premium
Quest Diagnostics last week said that it is now offering a molecular diagnostic test that can detect chromosome abnormalities associated with 85 developmental disorders affecting children.
 
The ClariSure is a microarray-based comparative genomic hybridization test that will be used to diagnose patients with mental retardation and Down syndrome among other disorders. Quest said it expects to provide physicians with test results within five days of receiving specimens at one of its facilities.
 
The test is based on technologies developed by Quest’s Nichols Institute and other licensed methodologies.
 

“While CGH microarrays are often used for research purposes, the considerable expertise and development required to commercialize these technologies has limited their use for diagnostic testing,” Joyce Schwartz, vice president and chief laboratory officer for Quest, said in a statement. She said the ClariSure assay “bridges the gap” between scientific research and clinical diagnostic testing and provides a faster diagnosis of developmental disorders.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.